Adaptive Biotechnologies
| General Information | |
| Business: |
We are advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how it detects and treats disease in that patient. |
| Industry: | BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) |
| Employees: | 346 |
| Founded: | 2009 |
| Contact Information | |
| Address | 1551 Eastlake Avenue East, Suite 200, Seattle, Washington 98102, US |
| Phone Number | (206) 659-0067 |
| Web Address | http://www.adaptivebiotech.com |
| View Prospectus: | Adaptive Biotechnologies |
| Financial Information | |
| Market Cap | $2419.5mil |
| Revenues | $58.6 mil (last 12 months) |
| Net Income | $-52.6 mil (last 12 months) |
| IPO Profile | |
| Symbol | ADPT |
| Exchange | NASDAQ |
| Shares (millions): | 15.0 |
| Price range | $20.00 - $20.00 |
| Est. $ Volume | $300.0 mil |
| Manager / Joint Managers | Goldman Sachs/ J.P. Morgan/ BofA Merrill Lynch |
| CO-Managers | Cowen/ Guggenheim Securities/ William Blair/ BTIG |
| Expected To Trade: | 6/27/2019 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |